Published in Cancer Weekly, March 21st, 2000
The clinical trial is currently open at two sites in France.
According to Dr. John Reno, IBC Pharmaceuticals, "Pentacea delivers cytotoxic radiation directly to patient's tumors that express carcinoembryonic antigen (CEA). CEA is expressed on most major solid tumors including those of the breast, colon, and lung.
"Pentacea is the first commercial drug to be developed using the company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.